We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+42.67%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.86B
AUM Growth
+$458M
Cap. Flow
+$74.4M
Cap. Flow %
4%
Top 10 Hldgs %
60.44%
Holding
79
New
30
Increased
3
Reduced
8
Closed
14
Avg Time Held Equity + Options
2.1 quarters
Top 10 Avg Time Held Equity + Options
2.6 quarters
Top 20 Avg Time Held Equity + Options
3.5 quarters
Avg Time Held Equity only
2.1 quarters
Top 10 Avg Time Held Equity only
2.6 quarters
Top 20 Avg Time Held Equity only
3.7 quarters

Top Buys

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$84.6M
2
STTK icon
Shattuck Labs
STTK
+$79M
3
SLDB icon
Solid Biosciences
SLDB
+$33.6M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$18.9M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.9M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$99.6M
2
STRO icon
Sutro Biopharma
STRO
+$50M
3
SURF
Surface Oncology, Inc. Common Stock
SURF
+$28.5M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.9M
5
CBIO icon
Crescent Biopharma
CBIO
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.73%
2 Miscellaneous 5.76%
3 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XNCR icon
1
Xencor
XNCR
$1.75B
$198M 10.67%
4,547,072
– –
2018 Q4
8 quarters
RLAY icon
2
Relay Therapeutics
RLAY
$3.8B
$133M 7.15%
3,200,649
– –
2020 Q3
1 quarter
STTK icon
3
Shattuck Labs
STTK
$551M
$129M 6.92%
+2,456,854
New +$79M
2020 Q4
0 quarters
SPRY icon
4
ARS Pharmaceuticals
SPRY
$403M
$117M 6.31%
+2,533,635
New +$84.6M
2020 Q4
0 quarters
PRTA icon
5
Prothena Corp
PRTA
$429M
$113M 6.09%
9,426,640
– –
2018 Q4
8 quarters
ORIC icon
6
Oric Pharmaceuticals
ORIC
$1.17B
$105M 5.63%
3,092,218
+450,000
+17% +$12.9M
2020 Q2
2 quarters
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$102M 5.48%
464,298
– –
2018 Q4
8 quarters
MORF icon
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$95.3M 5.12%
2,839,884
– –
2019 Q2
6 quarters
ANAB icon
9
AnaptysBio
ANAB
$1.36B
$69.3M 3.73%
3,223,324
– –
2019 Q4
4 quarters
BIIB icon
10
CALL
Biogen
BIIB
$33.8B
$62.2M 3.34%
+254,100
New +$65.6M
2020 Q4
0 quarters
SLDB icon
11
Solid Biosciences
SLDB
$624M
$60.5M 3.25%
+531,847
New +$33.6M
2020 Q4
0 quarters
KURA icon
12
Kura Oncology
KURA
$874M
$57.9M 3.11%
1,773,037
-2,835,492
-62% -$99.6M
2015 Q4
20 quarters
RCUS icon
13
Arcus Biosciences
RCUS
$2.87B
$57M 3.06%
2,195,892
+385,892
+21% +$9.34M
2018 Q1
11 quarters
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$53.7M 2.89%
2,103,950
– –
2020 Q2
2 quarters
NRIX icon
15
Nurix Therapeutics
NRIX
$2.42B
$50.8M 2.73%
1,544,019
+351,863
+30% +$11.7M
2020 Q3
1 quarter
NGNE icon
16
Neurogene
NGNE
$431M
$44M 2.37%
156,135
-37,012
-19% -$9.04M
2018 Q2
10 quarters
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$39.2M 2.11%
2,426,685
– –
2019 Q2
6 quarters
AKUS
18
DELISTED
Akouos Inc
AKUS
$39.2M 2.11%
1,975,984
– –
2020 Q2
2 quarters
AMTI
19
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$35.4M 1.9%
1,150,000
– –
2020 Q2
2 quarters
GERN icon
20
Geron
GERN
$771M
$30.1M 1.62%
18,939,925
-290,844
-2% -$530K
2020 Q2
2 quarters
KDNY
21
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$19.8M 1.07%
+1,250,001
New +$18.9M
2020 Q4
0 quarters
KLRS icon
22
Kalaris Therapeutics
KLRS
$53.1M
$17.2M 0.92%
19,435
– –
2020 Q3
1 quarter
GRTS icon
23
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$13.5M 0.72%
+3,421,287
New +$10.3M
2020 Q4
0 quarters
ACIU icon
24
AC Immune
ACIU
$239M
$12.5M 0.67%
+2,410,240
New +$12.3M
2020 Q4
0 quarters
KRON icon
25
DELISTED
Kronos Bio
KRON
$11.6M 0.62%
+387,357
New +$12.2M
2020 Q4
0 quarters
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2020 Portfolio in Review

As of Q4 2020, EcoR1 Capital held 79 positions worth $1.86B, up 33% from $1.4B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $74.4M of net new capital in Q4 2020, opening 30 new positions and adding to 3 existing holdings. Its largest new stake was ARS Pharmaceuticals: 2,533,635 shares worth $117M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Kura Oncology, an estimated $99.6M trimmed.

  • EcoR1 Capital's largest Q4 2020 buy was ARS Pharmaceuticals: 2,533,635 shares worth $117M.
  • EcoR1 Capital added most to Oric Pharmaceuticals in Q4 2020, an estimated $12.9M increase.
  • EcoR1 Capital's biggest Q4 2020 reduction was Kura Oncology, cutting an estimated $99.6M.
  • EcoR1 Capital fully exited Assembly Biosciences in Q4 2020, selling an estimated $24.9M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.86B portfolio in Q4 2020.
  • EcoR1 Capital opened 30 new positions and closed 14 in Q4 2020.
  • EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $1.86B.

Based on EcoR1 Capital's 13F filing for Q4 2020, filed 16 Feb 2021.